Reviva Pharmaceuticals Holdings, Inc. Proceeds from Issuance or Sale of Equity
Reviva Pharmaceuticals Holdings, Inc. (RVPH) had Proceeds from Issuance or Sale of Equity of $8.50 million as of 2022-09-08, per its 10-K filed 2023-03-30.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOrSaleOfEquity · last filed 2023-03-30
- Reviva Pharmaceuticals Holdings, Inc. proceeds from issuance or sale of equity for the quarter ending 2021-09-30 was $0.00.
- Reviva Pharmaceuticals Holdings, Inc. proceeds from issuance or sale of equity for the quarter ending 2020-09-30 was $0.00.
| Period end | Proceeds from Issuance or Sale of Equity | Proceeds from Issuance or Sale of Equity 3 month | Proceeds from Issuance or Sale of Equity 6 month | Proceeds from Issuance or Sale of Equity 9 month |
|---|---|---|---|---|
| 2022-09-08 | $8.50M 10-K · filed 2023-03-30 | |||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $31.50M 10-Q · filed 2021-11-15 | ||
| 2021-06-30 | $31.50M 10-Q · filed 2021-08-16 | |||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $0.00 10-Q · filed 2021-11-15 | ||
| 2020-06-30 | $0.00 10-Q · filed 2021-08-16 | |||
| 2018-08-30 | $8.60M 10-K · filed 2020-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |